The treatment of dementia with acetylcholinesterase inhibitors: analysis of plasma concentrations, drug interactions and therapeutic effect as a function of genetic polymorphisms [Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhangigkeit von genetischen Polymorphismen]

Trial Profile

The treatment of dementia with acetylcholinesterase inhibitors: analysis of plasma concentrations, drug interactions and therapeutic effect as a function of genetic polymorphisms [Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhangigkeit von genetischen Polymorphismen]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2011

At a glance

  • Drugs Donepezil (Primary) ; Galantamine (Primary) ; Rivastigmine (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 24 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top